Background: Survival rates among breast cancer patients and the number of patients living with treatment side effects have improved, leading to increased focus on quality of life (QOL). The objective of this study was to determine the efficacy of CoQ 10 on QOL scores among breast cancer patients in Iranian undergoing tamoxifen therapy. Methods: Thirty breast cancer patients were randomized into two groups. The first group received 100 mg CoQ 10 , and the second group took fplacebo once a day for 8 weeks. QOL was evaluated by a standard QOL questionnaire and a specific questionnaire on QOL of breast cancer patients at baseline and the end of the study. Also, physical activity of patients was assessed with the IPAQ questionnaire and dietary intake determined by a 3-day dietary record. Results: The data of 30 subjects were analyzed. According to QOL C30 data, CoQ 10 led to a significant increase in physical functioning (P=0.029), emotional functioning (P=0.031), and cognitive functioning (P=0.023) compared to placebo. Symptom scales revealed a notable reduction in appetite loss in the first group (P=0.01). Global health status showed no significant changes in either study arm. On the QOL BR23, progress in functions and decline in symptoms were not statistically significant. Arm symptoms showed significant reduction (P=0.022) in patients that received placebo. Conclusion: This trial indicates that CoQ 10 supplementation has effects in ameliorating some dimensions of QOL in breast cancer patients. To generalize the results, larger and longer intervention studies are needed. Clinical Trial Registration: IRCT2015042021874N1.
Background
Breast cancer is the most common cancer in women in both developed and less developed countries. It is estimated that worldwide, over 627,000 women died in 2018 due to breast cancer. 1 More than 14% of mortality causes in women in Iran are related to breast cancer. 2 Although the incidence rate of breast cancer in Asian countries (such as Iran) is lower than in Western countries, the trend in Iran is rising. 3 Breast cancer-survival rates differ considerably worldwide, ranging from 80% or over in North America, Sweden, and Japan to around 60% in middle-income countries and <40% in low-income countries. 4 With regard to cancer, survival rate is considered one of the main prognostic indicators of the disease. In addition to various demographic factors, this index is influenced by the stage of cancer when diagnosed and the type of treatment, or in other words, diagnostic and therapeutic measures. 5, 6 Studies conducted in Iran's provinces over the past decade have estimated the 5-year survival rate in breast cancer patients to be 48%-87%. 7 These differences may be due to patients' biological, racial/ genetic, geographical, socioeconomic, and cultural differences, and also different treatment options and patients' access to these facilities. The World Health Organization defines health as "a state of complete physical, mental, and social well-being, not merely the absence of disease or infirmity". Therefore, this is necessary to comprise an estimation of well-being, evaluated by quantifying advances in quality of life (QOL) related to health care, in addition to changes in the frequency and severity of diseases by measuring health and health-care consequences. 8 Researchers have proposed that at least 80% of cancer patients, particularly those undergoing multiple treatments, experience notable levels of fatigue that may negatively affect their QOL, emotional well-being, and treatment tolerance. 9 Some practical techniques for breast cancer patients' treatment are mastectomy, radiotherapy, and chemotherapy plus hormonal therapy. Although these effective treatment methods lead to increased survival rates in breast cancer patients, the QOL of such patients is fluctuating and often poor. 10, 11 For example, long-term radiotherapy or chemotherapy often results in loss of self-confidence, substantial disruption in physical functioning, mental health, and wellbeing, and impaired QOL. In addition, total or partial mastectomy could be one of the reasons of psychological and emotional problems such as depression and anxiety, all affect QOL of breast cancer patients.
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CoQ 10 is a lipophilic inner mitochondrial membrane cofactor with ten isoprenoid units that shuttle electrons in the formation of ATP, with wide distribution in the human body.
14 Decreased critical levels of CoQ 10 result in the reduction of energy production and antioxidant-protection capacity in cancer patients, due to two factors: cancer is more prevalent in older persons and CoQ 10 synthesis declines with aging; and older cancer patients have multiple complications, such as oxidative stress, chemo/radiotherapy, and anticancer-drug usage, which lead to reductions in CoQ 10 levels. 15 Studies on the effectiveness of CoQ 10 on QOL in different diseases have indicated that this supplement can have a beneficial effect on QOL. [16] [17] [18] However, there have been few studies on breast cancer, 9 and to our knowledge, a trial evaluating the effect of CoQ 10 alone in breast cancer patients has not been done yet. Considering the high prevalence of breast cancer, in addition to its importance and effects on all life dimensions of patients, focusing on QOL as it relates to health and finding solutions to ameliorate QOL of these patients seems necessary. Therefore, we aimed to determine the efficacy of CoQ 10 on QOL scores that had been collected in a double-blind randomized clinical trial for Iranian women with breast cancer.
Methods Patients
The target population of this randomized A total of 143 women diagnosed as breast cancer patients with positive estrogen receptor were assessed for eligibility, and 30 patients met the inclusion criteria. Subjects were divided into two groups using simple random sampling: 15 breast cancer patients received 100 mg/ day CoQ 10 orally (group A), and 15 breast cancer patients took 100 mg/day placebo (wheat flour encapsulated similarly in shape and color to the desired supplement, group B) for 2 months. For better absorption of supplements, subjects were advised to take them within meals, and compliance was calculated by counting the number of tablets given to each subject and recollected at the end of the trial. All procedures were performed at the Medical Oncology Department of Shaffa Hospital by the researchers, and patients were followed up by phone call weekly.
Assessment of Dietary Intake
A validated questionnaire and 3-day dietary record, including two weekdays and one weekend day, under supervision of a dietitian were completed by all subjects before and after the end of the study period. Dietary energy and nutrient intake were analyzed by Nutritionist IV software. Soy and soy products use were forbidden, because of estrogen-agonistic/antagonistic effects. 19 
Assessment of Quality of Life
The QOL of patients was evaluated using a standard QOL questionnaire (C30) and a specific questionnaire on QOL of breast cancer patients (BR23). The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 encompasses 30 items, including five functional scales (physical, role, emotional, cognitive, and social) and nine symptom scales (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) plus one global health scale. The BR23 questionnaire consists of 23 questions designed to quantify QOL in breast cancer, including five functional scales (body image, sexual functioning, sexual enjoyment, future perspectives), and four symptom scales (systematic therapy side effects, breast symptom, arm symptoms, upset about hair loss). 20 The EORTC QLQ was translated into Persian and validated by Safaee et al 21 and Montazeri et al. 22 In general, the findings of these studies indicated that the Iranian version of the EORTC QLQ-C30 and QLQ-BR23 were reliable and valid measures of QOL in breast cancer patients and can be used in clinical trials and studies of outcome research in oncology. After information collection from patients by QOL questionnaires, raw scores for each subscale were calculated and then changed to 0-100 scales according to the guidelines of the EORTC scoring manual. Higher scores on functioning scales and global health status indicate better QOL or a high level of functioning. In the case of symptom scales, higher scores indicate the higher levels of symptoms, a critical indicator of QOL. 9 Physical activity was assessed by the International Physical Activity Questionnaire, 23 which asks subjects about their physical activity in five sections: job-related, transportation, housework, recreation, and time spent sitting). In order to analyze this questionnaire, the relevant guidelines were used.
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Sample Size
According to Premkumar et al, using Minitab software with 95% CI and test power of 90%, the sample size in each group was set at ten. To increase the accuracy of the study and to prevent a 50% drop, the sample size was increased to 15 individuals.
Statistical Analysis
Data were analyzed with SPSS version 22. The ShapiroWilk test was used to specify the normality of the variables' distribution. The multi-item scales of EORTC QLQ-C30 and all subscales of BR23 were analyzed for relationships. ANCOVA and least significant-difference tests were applied to determine associations between study groups and independent/dependent variables measured before and after the trial. Dietary energy and nutrient intake were analyzed with Nutritionist IV. Values are presented as means ± SD, with significance set at P<0.05.
Results
Thirty patients (15 CoQ 10 and 15 Placebo) completed the study. Some subject characteristics at the beginning of the study (Table 1) were not significantly different between placebo and CoQ 10 groups. Dietary intake of energy and macronutrients was assessed and showed no differences between groups at baseline and had not changed at the end of 2 months (Table 2 ). Research has revealed that physical activity may affect CoQ 10 plasma levels, 25 and thus this was determined using the International Physical Activity Questionnaire (Table 3 ). No significant difference was observed between groups. Tables 4 and 5 shows the effect of CoQ 10 on QOL components during the two phases of measurement and their changes during the study. According to QOL C30 data, analysis of the questionnaires showed that supplementation with CoQ 10 significantly increased physical functioning (P=0.029) compared to placebo. Also, emotional functioning and cognitive functioning of patients after supplementation significantly increased (P=0.031 and P=0.023, respectively). An insignificant increasing trend was observed on other functional scales, indicating better QOL than at the beginning of the study. Symptom scales revealed a notable reduction in appetite loss in the CoQ 10 group (P=0.01). Global health status showed no significant changes in the CoQ 10 or placebo arm. In the case of symptom scales, insignificant decreases were found in fatigue, nausea and vomiting, pain, insomnia, and constipation. However, financial problems increased significantly in the intervention group (P<0.0001). On the QOL BR23, progress on functional scales (body image, sexual functioning, sexual enjoyment, and future perspectives) and decline on symptom scales (systemic therapy side effects, breast symptoms, and upset with hair loss) were not statistically significant. Arm symptoms (BRAS) showed significant reduction (P=0.022) in subjects receiving placebo.
Discussion
Cancer treatments, such as chemotherapy, in breast cancer patients can cause several side effects and symptoms, including physical, functional, psychological and social difficulties (anxiety, depression, pain, fatigue, and arm morbidity), that affect QOL. Clinical trials have demonstrated that evaluation of QOL and making changes leads to treatment improvement, increasing survival in cancer patients. 26 It has been
shown that numerous disease processes associated with CoQ 10 deficiency can benefit from CoQ 10 supplementation, including cancer. In this study, we evaluated the efficacy of CoQ 10 on QOL in breast cancer patients. 27 The results of this study demonstrated that oral CoQ 10 supplementation (100 mg/day) for 8 weeks had beneficial effects on physical, emotional, and cognitive functioning, as well as appetite. However, global health status remained unchanged after CoQ 10 supplementation. Furthermore, there was a not-inconsiderable improvement in other dimensions of EORTC questionnaire scores in the supplemented group that showed nonstatistically significant but clinical importance of CoQ 10 in ameliorating QOL. These outcomes were obtained despite the low sample size and short study duration, and for better understanding of Notes: *Difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA. Notes: P-values for difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA. Metabolic equivalent: 1 MET = 1 kcal/kg/hour). *This section includes two areas of walking and cycling. Due to the negative response to participation in cycling, this area was removed in the data analysis. Notes: *Difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA. P<0.05 significant.
CoQ 10 effects on QOL of breast cancer patients, more clinical trials are needed. Although the effects of CoQ 10 on QOL among patients with other chronic diseases have been studied in several clinical trials with conflicting results, to our knowledge this is the first study indicating the effect of CoQ 10 supplementation alone on QOL in patients with breast cancer. There have been some clinical trials done to assess the effect of CoQ 10 supplementation alone on QOL in breast cancer patients, and the their results were in line with our study.
Guilbot et al suggested that 12 weeks of a combination of feverfew, magnesium, and CoQ 10 at a dosage of 100 mg/day for migraine prophylaxis significantly reduced the number of days with migraine headache and improved QOL. 16 In another study, Sharifi et al showed that both a therapeutic lifestyle-change diet and supplementation with CoQ 10 (150 mg/day) and L-carnitine had a positive effect on the physical and emotional subscales of the MacNew questionnaire in patients with myocardial infarction. 17 In addition, Morris et al illustrated the CoQ 10 's potential role in improving QOL in patients with Parkinson's disease and fibromyalgia. Also, it showed antidepressive effects and significantly reduced fatigue and improved ergonomic performance during exercise. 28 Other studies assessing the effect of CoQ 10 in combination with other nutrients, such as NADH, in chronic fatigue syndrome 29 and high-dose micronutrients in patients with chronic heart failure 18 have indicated significant improvement in QOL and other dimensions of health care. In contrast to our study, clinical trials have revealed conflicting results, eg, 300 mg/day CoQ 10 or placebo, each combined with 300 IU vitamin E, divided into three daily doses for 24 weeks led to increase in plasma CoQ 10 levels, but did not result in improved self-reported fatigue or QOL in breast cancer patients. 9 Also, a study on amino-acid jelly containing CoQ 10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy showed that EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups. 30 Muscle strength, muscle endurance, and QOL increased statistically Notes: *Difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA. P<0.05 is significant.
significantly in all postpolio-syndrome patients in both groups of CoQ 10 supplementation and placebo, which revealed CoQ 10 had no beneficial effect. 31 Multiple roles as an antioxidant, a membrane stabilizer, and specifically mitochondria regulation, which optimize cellenergy generation, are some aspects of cellular CoQ 10 functioning. Lowered CoQ 10 levels are connected with high inflammation, oxidative/nitrosative stress, and dysfunction of mitochondria, which are activated by intracellular signaling pathways, including NFκB, MAPK, and JAK-STAT. As such, proteins and fatty acids in cell membranes can be attacked by ROS, which reduces membrane fluidity and diminishes the performance of cell-membrane receptors and ion channels, thus disrupting intercellular and intracellular signaling processes and leading to such disorders as fatigue, hyperalgesia, depression, and neurodegenerative processes. 27, 32, 33 Also, in depleted levels of CoQ 10 , uncoupling proteins do not function correctly, which causes inability in regulating cellular fuel metabolism and other ATP-dependent processes. 27, 34 Some genes involved in mitochondrial biogenesis and replication due to increasing energy demands are under CoQ 10 control. As a consequence, stimulating oxidative metabolism in response to increased demands for energy could be affected in CoQ 10 deficiencys. 35 CoQ 10 treatment decreases fatigue, depression, and hyperalgesia through its anti-inflammatory, antioxidant, and neuroprotective effects. Also, it decreases muscle weakness, increases walking distance, and improves exercise tolerance and oxygen consumption by modification of the performance of complex I of the electron-transfer chain. 28 Given that, sex and dietary intake are considered confounding factors in QOL. 36, 37 Limiting our sample to women and records of dietary intake are a couple of the strengths of our study.
Conclusion
In this study, we discovered proof demonstrating significant effects of CoQ 10 on physical, social, and mental conditions in women with breast cancer. In short, the supplemented patients showed better QOL at the end of the study. Separate studies should be conducted in different age-groups and larger populations for longer periods to generalize the evidence gained.
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